Basic Citalopram Information

• INN (International Nonproprietary Name): Citalopram.
• Brand Names Available In United Kingdom: Cipramil, Citalopram Teva, Sandoz.
• ATC Code: N06AB04.
• Forms & Dosages: Film-coated tablets 10 mg, 20 mg, 40 mg; oral solution/drops 10 mg/mL and 20 mg/mL; IV solution (10 mg/2 mL, 20 mg/2 mL) noted as rare and mainly for hospitals.
• Manufacturers In United Kingdom: Local manufacturers and suppliers include Arena Group, Actavis (now Teva), Zentiva, Sandoz, Hexal, AL and Torrent, with global suppliers such as Lundbeck, Teva, Sandoz and Accord Healthcare.
• Registration Status In United Kingdom: Not specified.
• OTC / Rx Classification: Prescription only (Rx), not available over-the-counter in regulated markets.

Latest Research Highlights (UK & EU 2022–2025)

What Do Clinicians Want To Know From Recent Studies?

Recent UK and EU research from 2022–2025 emphasises three consistent findings for citalopram: modest but clinically meaningful efficacy for major depressive disorder in primary care, a continuing safety focus on dose-dependent QT prolongation, and real-world discontinuation driven by sexual dysfunction and withdrawal symptoms.

Large pharmacoepidemiology analyses using NHS-linked datasets show adherence gaps after three months and higher switching rates to alternatives such as sertraline or escitalopram where side effects occur.

Systematic reviews and network meta-analyses in this period position citalopram as broadly effective but not superior to escitalopram for tolerability.

Regulatory surveillance from MHRA and EMA continues to recommend ECG consideration at higher doses or in patients with cardiac risk.

Practical implication: prescribers should balance comparable efficacy against tolerability and QT risk when choosing citalopram.

Real Data Reminder: ATC N06AB04; standard adult 20 mg/day with a maximum of 40 mg/day; elderly maximum 20 mg/day.

Clinical Effectiveness In The UK

Will Patients Feel Better And When?

NHS primary and secondary care audits show citalopram is commonly prescribed for major depressive disorder and anxiety-spectrum disorders.

Improvements in sleep, mood and daily function are often reported within one to four weeks when adherence is maintained.

Remission rates are usually measurable by six to twelve weeks with continued treatment and appropriate dose adjustment.

Real-world NHS datasets report many patients require dose adjustment or a switch within eight to twelve weeks because of side effects or inadequate response.

IAPT services frequently combine psychotherapy with SSRI initiation and report better functional outcomes than medication alone for mild to moderate depression.

Product Guidance: Start at 20 mg/day, up-titrate to 40 mg/day where tolerated, and cap at 20 mg/day in elderly patients.

Clinicians should document baseline ECG if cardiac risk factors are present and record shared decision-making in the patient record.

Indications And Expanded Uses (MHRA & NHS Context)

What Is Citalopram Licensed For And When Is It Used Off-Label?

MHRA-approved indications centre on major depressive disorder and several anxiety disorders.

NHS practice also uses citalopram for panic disorder, social phobia and, where clinically appropriate, obsessive-compulsive disorder.

Typical regimens from product information are: for MDD start 20 mg/day with a maximum of 40 mg/day, and for OCD and some anxiety disorders starting doses around 10 mg/day with increases to 20–40 mg/day as tolerated.

Off-label prescribing in UK private clinics can include chronic pain syndromes or functional disorders, but such uses require clear documentation and patient consent.

NHS best practice advises continuing antidepressant treatment for at least six months after remission for a first episode, and longer for recurrent episodes or severe illness.

• MHRA-Approved Indications: Major depressive disorder, certain anxiety disorders.
• Common NHS Uses (Including Specialist Clinics): Panic disorder, social phobia, OCD in specialist care.
• Off-Label Uses (Require Consent): Chronic pain, functional disorders.

Remember prescription-only status and follow NHS prescription processes and documentation requirements.

Composition And Brand Landscape (UK Focus)

Which Brands, Strengths And Forms Will Patients See In The Pharmacy?

Active ingredient is citalopram hydrobromide, marketed under the INN citalopram.

Available formulations in the UK include film-coated tablets in 10 mg, 20 mg and 40 mg and oral solutions/drops typically at 10 mg/mL and 20 mg/mL.

Common brands and generics in the UK and EU are Cipramil, Citalopram Teva, Sandoz and a range of generics from Teva, Zentiva and Accord.

Typical packaging in the UK is foil blisters for tablets and amber bottles with droppers for oral solutions, labelled to MHRA requirements.

Generics dominate NHS formularies because of cost pressures, and pharmacies dispense branded or generic products according to prescription and availability.

Pharmacists should counsel on formulation differences, especially dose conversions between drops and tablets, and advise storage below 25°C.

Contraindications And Special Precautions

Who Should Not Take Citalopram Or Take It With Caution?

Absolute contraindications include hypersensitivity to citalopram or other SSRIs, concurrent use with monoamine oxidase inhibitors or within two weeks of MAOI discontinuation, and use with pimozide or other known QT-prolonging agents.

Relative contraindications include a history of seizures, current or past mania or bipolar disorder, unstable cardiac disease, and severe hepatic or renal impairment.

Elderly patients aged 65 and older have increased vulnerability to QT prolongation and should not exceed 20 mg/day.

Pregnancy and breastfeeding require specialist risk–benefit discussion and liaison with perinatal mental health services.

Advise patients about possible somnolence and dizziness and recommend caution when driving or operating machinery until they know how citalopram affects them.

• Absolute Contraindications: Hypersensitivity to SSRIs; MAOI co-administration or within two weeks; pimozide and other QT-prolonging drugs.
• Relative Contraindications / Use With Caution: Seizure disorder, bipolar disorder, unstable cardiac disease, severe liver or kidney dysfunction.

Data Box: Consider ECG when combining multiple QT risk factors, using higher doses, or treating elderly patients.

Dosage Guidelines (NHS-Recommended)

How Should Doses Be Started, Adjusted And Stopped?

Standard adult dose is 20 mg once daily, with titration to 40 mg once daily if needed and tolerated.

Elderly patients and those with hepatic impairment are generally limited to a maximum of 20 mg/day.

For panic disorder or social phobia clinicians may start at 10 mg/day and increase cautiously according to response and side effects.

When switching between SSRIs or antidepressant classes observe recommended washout periods, for example two weeks when stopping an MAOI before starting citalopram.

Discontinuation should be by gradual taper over weeks to months to reduce withdrawal symptoms, and the taper plan should be documented in primary care records.

Re-assessment checklist: review at two, four, eight and twelve weeks for efficacy, side effects and adherence.

Follow product guidance for missed-dose and overdose actions.

Interactions Overview (Drugs, Food, Monitoring)

Which Medicines And Substances Clash With Citalopram?

Citalopram is contraindicated with MAOIs due to the risk of serotonin syndrome.

Concurrent use with drugs that prolong the QT interval, such as pimozide and some antipsychotics and antiarrhythmics, is contraindicated.

Although citalopram has relatively low cytochrome P450 induction, combinations with potent CYP inhibitors warrant caution and dose review.

Alcohol may increase central nervous system effects and should be limited, especially during initiation of therapy.

MHRA Yellow Card reports frequently note interactions that lead to syncope or arrhythmia in polypharmacy contexts.

Recommend ECG and electrolyte checks when combining with other QT-prolonging drugs or in patients at risk of hypokalaemia.

Cultural Perceptions And Patient Habits In The UK

What Do Patients Say About Citalopram On Forums And In Pharmacy Consultations?

UK patient forums and NHS feedback channels show pragmatic attitudes: many accept SSRIs to stabilise mood while awaiting therapy, while others express concern about sexual side effects and withdrawal.

Community pharmacists are trusted sources for counselling and often guide adherence and side-effect management during face-to-face encounters.

NHS 111 and online NHS patient portals are frequently used for early advice and triage.

Electronic prescriptions and online pharmacies have changed access but raise concerns about continuity of care and verification.

Stigma varies by age and region, with younger patients often preferring digital therapy adjuncts to medication alone.

• Patient Habits: Use of NHS portals for symptom tracking and pharmacy counselling for side-effect management.
• Access Patterns: Electronic prescriptions and online ordering are common, but continuity with GP record is important.

Case vignette: A 28-year-old patient phones a community pharmacist worried about reduced libido after four weeks on citalopram 20 mg; the pharmacist documents concerns, advises the patient to see their GP for a review, and updates the NHS record.

Shared decision-making and documentation in the NHS record improve adherence and safety.

Availability And Pricing Patterns (UK Regions & Pharmacies)

How Easy Is It To Get Citalopram And What Does It Cost?

Citalopram is prescription-only across the UK and widely stocked by major chains such as Boots and LloydsPharmacy and independent pharmacies.

Generics from Teva, Zentiva and Sandoz reduce cost pressures on NHS formularies and influence dispensing choices.

Prescription charging differs across the UK: prescriptions are free in Scotland, Wales and Northern Ireland, while in England patients pay the standard prescription charge unless exempt.

These regional differences affect dispensing patterns and choices between branded and generic products.

For hospital formularies, IV forms are rare and mainly found in inpatient settings.

Storage guidance from product information: store below 25°C, protect from light and moisture, and keep in original packaging.

In our online pharmacy, citalopram is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Comparable Medicines And Prescribing Preferences

How Does Citalopram Compare With Other Antidepressants?

Common alternatives on NHS formularies include sertraline, escitalopram, fluoxetine and paroxetine.

Escitalopram is often cited for tolerability, sertraline for anxiety comorbidity, fluoxetine for a long half-life which eases withdrawal, and paroxetine for efficacy but with higher anticholinergic burden and withdrawal risk.

SNRIs such as venlafaxine and duloxetine are chosen for specific symptom profiles or when SSRI response is inadequate.

For many prescribers citalopram remains a cost-effective first-line SSRI, but choice should be individualised by side-effect profile, cardiac history and potential drug interactions.

Switching decisions should follow recommended washout and tapering protocols and be recorded in the NHS record.

FAQ Section (Common NHS Patient Questions)

What Questions Do Patients Ask Most Often?

Q1: How long until citalopram works? A: Some improvement can occur in 1–4 weeks, with therapeutic response often by 6–12 weeks; continue as advised by your prescriber.

Q2: Can I drink alcohol while on citalopram? A: Alcohol can increase drowsiness and worsen mood, so limit or avoid alcohol particularly during initiation.

Q3: What about sexual side effects? A: Sexual dysfunction is common; patients should discuss this with their GP or pharmacist — options include dose timing, switching antidepressant, or specialist interventions.

Q4: Is an ECG needed? A: Not routinely for most patients, but ECG is recommended if you have cardiac disease, are over 65, are on higher doses or are taking other QT-prolonging drugs.

Links and further reading: advise patients to consult NHS pages and MHRA safety advice for up-to-date guidance.

Guidelines For Proper Use (Pharmacist Counselling + NHS Resources)

What Should Pharmacists Say At The Counter?

Confirm the indication and review current medicines for interactions, especially MAOIs, pimozide and QT-prolonging drugs.

Advise on dose and timing, expected onset of benefit and common side effects such as nausea, sweating and sexual dysfunction.

Emphasise not to stop abruptly and provide a documented taper plan when discontinuing.

Encourage registration with the local GP and use of NHS patient portals for symptom tracking.

Signpost perinatal mental health services, IAPT and NHS 111 for urgent or specialist advice.

• Dispensing Checklist: Verify prescription, supply PIL, counsel on storage (<25°C), missed-dose guidance and record counselling in the NHS summary care record.
• Reporting: Encourage Yellow Card reporting for suspected adverse reactions and follow MHRA guidance.

Concise counselling script for pharmacy teams: explain indication, how to take the medicine, what to expect in 1–4 weeks, when to seek help, and document the conversation in the patient record.

Delivery Across United Kingdom

Final Practical Notes

Key Facts To Remind Patients And Clinicians.

ATC classification is N06AB04 and the active compound is citalopram hydrobromide.

Standard adult dosing starts at 20 mg once daily, with a 40 mg/day maximum and a 20 mg/day cap for elderly patients.

Store products below 25°C and keep tablets in their blister until use.

Pharmacists should record counselling in the NHS summary care record and report adverse events via the Yellow Card scheme.

Where cardiac risk exists or when higher doses are considered, arrange baseline ECG and review concurrently prescribed QT-prolonging medicines.

For further NHS guidance consult local formularies and MHRA safety advice as required.